42939 Remibrutinib Treatment Improves Itch and Sleep in Chronic Spontaneous Urticaria Patients: Phase 2b Study Results

Connie Hsu,Robert Snyder,Lee Clore,Vipul Jain,Ana Gimenez-Arnau,Karine Lheritier,Pauline Walsh,Sibylle Haemmerle,Michael Wells,Ivan Nikolaev,Marcus Maurer

Journal of the American Academy of Dermatology（2023）

引用 0|浏览16

暂无评分

摘要

Introduction: Chronic spontaneous urticaria (CSU) is characterized by wheals (hives) and/or angioedema (>6 weeks) and has a major impact on patients’ wellbeing. We explored the eﬀect of remibrutinib (LOU064), a novel oral Bruton's Tyrosine Kinase inhibitor, on itch severity and sleep interference in CSU patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要